Myriam Lemmens
Overview
Explore the profile of Myriam Lemmens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yasuda S, Bando K, Henry M, Libertini S, Watanabe T, Bando H, et al.
Stem Cells Transl Med
. 2024 Aug;
13(10):1001-1014.
PMID: 39120125
The presence of residual undifferentiated pluripotent stem cells (PSCs) in PSC-derived cell therapy products (CTPs) is a major safety issue for their clinical application, due to the potential risk of...
2.
Lemmens M, Dorsheimer L, Zeller A, Dietz-Baum Y
Mutat Res Genet Toxicol Environ Mutagen
. 2024 May;
896:503767.
PMID: 38821669
Gene therapies have emerged as promising treatments for various conditions including inherited diseases as well as cancer. Ensuring their safe clinical application requires the development of appropriate safety testing strategies....
3.
Lemmens M, Perner J, Potgeter L, Zogg M, Thiruchelvam S, Muller M, et al.
Cytotherapy
. 2022 Nov;
25(1):59-67.
PMID: 36319564
Background: Engineered tissues and cell therapies based on human induced pluripotent stem cells (iPSCs) represent a promising approach for novel medicines. However, iPSC-derived cells and tissues may contain residual undifferentiated...
4.
Lemmens M, Fischer B, Zogg M, Rodrigues L, Kerr G, Del Rio-Espinola A, et al.
Mol Ther Methods Clin Dev
. 2021 Oct;
23:241-253.
PMID: 34703845
Off-target editing is one of the main safety concerns for the use of CRISPR-Cas9 genome editing in gene therapy. These unwanted modifications could lead to malignant transformation, which renders tumorigenicity...